Author:
Olivieri Bianca,Ghilarducci Alessandro,Nalin Francesca,Bonadonna Patrizia
Abstract
Purpose of review
Patients with mast cell disorders frequently experience symptoms from excessive mediator release like histamine and tryptase, ranging from mild flushing to severe anaphylactic responses. Hypersensitivity reactions (HRs) to drugs are a major cause of anaphylaxis in these patients, who often worry about triggering mast cell degranulation when taking medications. The aim of this review is to explore the complex interactions between mast cell disorders and drug HRs, focusing on the clinical challenges of managing these conditions effectively to enhance understanding and guide safer clinical practices.
Recent findings
Among the drugs most commonly associated with hypersensitivity reactions in patients with mast cell disorders are non-steroidal anti-inflammatory drugs, antibiotics, and perioperative agents. Recent studies have highlighted the role of Mas-related G-protein coupled receptor member X2 (MRGPRX2) – a receptor involved in non-immunoglobulin E mediated mast cell degranulation – in exacerbating HRs. Investigations reveal varied drug tolerance among patients, underscoring the need for individual risk assessments.
Summary
Tailored diagnostic approaches are crucial for confirming drug allergies and assessing tolerance in patients with mastocytosis, preventing unnecessary medication avoidance and ensuring safety before acute situations arise.
Publisher
Ovid Technologies (Wolters Kluwer Health)